Acquired BRAF V600E mutation mediated resistance to osimertinib and responded to osimertinib, dabrafenib, and trametinib combination therapy
Y Huang, J Gan, K Guo, Y Deng, W Fang - Journal of Thoracic Oncology, 2019 - jto.org
BRAF V600E mutation accounts for approximately 1.5% of lung adenocarcinoma. 1 Clinical
studies have proven positive antitumor effect of dabrafenib, a BRAF inhibitor, plus trametinib,
an MEK inhibitor, in BRAF V600E–mutated NSCLC patients. 2, 3 BRAF V600E mutation
serves as one of the resistance mechanisms to osimertinib. 4, 5 A preclinical study has
confirmed that acquired osimertinib resistance mediated by BRAF V600E mutation could be
overcome by combined BRAF inhibitor encorafenib with osimertinib in vitro. 4 Whether …
studies have proven positive antitumor effect of dabrafenib, a BRAF inhibitor, plus trametinib,
an MEK inhibitor, in BRAF V600E–mutated NSCLC patients. 2, 3 BRAF V600E mutation
serves as one of the resistance mechanisms to osimertinib. 4, 5 A preclinical study has
confirmed that acquired osimertinib resistance mediated by BRAF V600E mutation could be
overcome by combined BRAF inhibitor encorafenib with osimertinib in vitro. 4 Whether …
